1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” The study evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth in patients with severe alopecia areata, using numeric rating scales for assessment. The analysis involved longitudinal ER modeling with ordinal regression to describe the efficacy of ritlecitinib on eyebrow and eyelash hair regrowth. The models indicated that the tested doses in the phase IIb/III clinical trial are effective, with the 50 mg dose being optimal for patients with impaired eyebrow and eyelash hair. The findings support the use of ritlecitinib as a treatment for alopecia areata, with the analysis methodology applicable to other ER studies involving ordinal categorical variables.
18 citations
,
July 2022 in “Frontiers in Immunology” Volatile organic compounds can cause inflammation and increase the risk of autoimmune diseases.
30 citations
,
September 2017 in “Environmental health perspectives” Exposure to Corexit dispersants during the oil spill cleanup was linked to increased respiratory and eye irritation symptoms in workers.
4 citations
,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
10 citations
,
July 2016 in “Clinical and translational science” Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.